This review summarizes proposed anticancer applications of beta-glucans from fungi, yeast, bacteria, and cereals. It discusses how structural properties may influence biological activity and describes immune-recognition pathways involving receptors such as Dectin-1, complement receptor 3, toll-like receptors, and glycolipids. The article brings together laboratory, animal, and clinical literature on immune activation and tumor-related outcomes. Because the evidence spans different beta-glucan sources and study designs, the conclusions cannot be applied automatically to Aureobasidium beta-glucan or interpreted as proof that beta-glucan treats cancer.
A review of beta-glucan structures, immune-recognition pathways, and experimental anticancer applications.
The evidence is heterogeneous and does not establish cancer-treatment efficacy for a specific beta-glucan product.
AI-generated summary for accessibility. Always refer to the original paper.
Noorbakhsh Varnosfaderani, Seyed Mostafa; Ebrahimzadeh, Farnoosh; Akbari Oryani, Mahsa; Khalili, Saeed; Almasi, Faezeh; Mosaddeghi Heris, Reza; Payandeh, Zahra; Li, Chen; Nabi Afjadi, Mohsen; Alagheband Bahrami, Armina. Potential promising anticancer applications of β-glucans: a review. Bioscience Reports. 2024. DOI: 10.1042/bsr20231686.
For scientific reference only. Not medical advice. Consult a qualified healthcare professional. See our Medical Disclaimer.